Newer & Emerging Areas of Dog Use in Research
While traditional regulatory toxicology slowly contracts, several scientific domains are expanding their use of dogs in ways that receive far less public scrutiny. Some involve purpose-bred laboratory beagles; others enroll client-owned pets. All raise distinct ethical questions that the declining-headline-numbers narrative obscures.
Gene Therapy & AAV Vectors
Dogs are unusually prominent in gene therapy because they harbor naturally occurring genetic diseases that closely model human conditions.
Canine models of Duchenne muscular dystrophy (DMD) have been central to AAV-based gene-therapy development for over a decade, generating pivotal data on vector biodistribution, immune responses, dose optimization, and long-term durability. The golden retriever muscular dystrophy (GRMD) model remains one of the most heavily relied-upon large-animal platforms for DMD candidates entering clinical trials.
In hemophilia, companion dogs with inherited clotting disorders serve as translational bridges between rodent proof-of-concept and human dosing. Long-term follow-up in canine hemophilia A and B models has been used to predict therapeutic response timelines in human patients.
The most celebrated success is RPE65-linked blindness: reversal of inherited retinal degeneration in Briard dogs preceded Luxturna, the first FDA-approved gene therapy for a genetic disease. Clinical reviewers explicitly connected the canine model outcomes to later human efficacy.
Regulatory driver: ICH S12 (implemented by FDA) formalizes nonclinical biodistribution as a core design element for gene therapies, effectively mandating large-animal studies for vector distribution and persistence. This guidance structurally anchors dog use in the gene-therapy pipeline even as other testing categories decline.
Immuno-Oncology & Comparative Cancer Trials
Pet dogs with naturally occurring cancers are being enrolled in trials that sit between traditional preclinical models and human studies.
The NCI-supported Comparative Oncology Trials Consortium (COTC) integrates clinical trials in pet dogs with spontaneous tumors into human drug-development pathways. Dogs develop many of the same cancers as humans — osteosarcoma, melanoma, lymphoma, bladder carcinoma — with intact immune systems, tumor heterogeneity, and treatment resistance patterns that rodent xenograft models cannot replicate.
Checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) are now being tested in canine cancer patients to evaluate combination strategies, biomarker selection, and resistance mechanisms before human trials. This domain is rapidly becoming “omics-heavy” — tumor sequencing, transcriptomics, spatial profiling — and enrollment is projected to grow with the precision-medicine pipeline.
Regulatory driver: FDA guidance on animal models for immuno-oncology recognizes spontaneous canine tumors as more predictive than syngeneic mouse models for immune-checkpoint therapy. The dogs are client-owned, not lab-bred, which creates a different ethical calculus — but they remain dogs in experimental protocols.
Military & Defense Research
Department of Defense programs use dogs in blast-injury, chemical exposure, hemorrhage, and detection-performance research that rarely appears in mainstream biomedical literature.
The U.S. Army Combat Capabilities Development Command conducts controlled studies on detection-dog performance using treadmill-and-olfactometer paradigms that measure how physical exertion, heat stress, and chemical environments affect scent-detection ability. The DHS Science and Technology Directorate maintains a dedicated Detection Canine program focused on improving explosives and narcotics detection for homeland-security missions.
Blast injury and hemorrhage models have historically used dogs to study battlefield trauma physiology, tourniquets, resuscitation fluids, and wound management protocols. Chemical-exposure research profiles contaminants encountered during operational deployments and disaster response, translating into PPE specifications and decontamination procedures for working dogs.
Emerging programs explore human–dog–robot teaming for search-and-rescue, pairing AI/autonomous systems with canine detection teams for faster localization in collapsed structures.
Why it is hard to track: Military research is driven by operational mission needs rather than publication incentives. Studies are scattered across niche journals, government technical reports, and conference proceedings. Operational sensitivities can limit detail even when results are published.
Imaging Studies (MRI, PET, CT)
What looks like “just a scan” is actually a chain of procedures — each session requires general anesthesia, vascular access, and recovery monitoring.
PET, MRI, and CT scans require immobilization, which means general anesthesia for dogs. A typical imaging session involves 12-hour fasting, propofol induction, endotracheal intubation, mechanical ventilation (for fMRI), radiotracer or contrast injection via catheter, the scan itself, and post-anesthesia recovery monitoring.
Research has demonstrated that anesthesia duration measurably alters brain FDG uptake in beagles, meaning repeated imaging sessions impose not only cumulative anesthesia exposure but physiologically meaningful changes that confound the data they are meant to collect. Functional MRI protocols use sevoflurane titrated to the minimum needed for immobilization.
Regulatory driver: Imaging endpoints are increasingly requested by FDA for gene-therapy biodistribution, neuroscience CNS-penetrant drugs, and oncology tumor-response assessment — expanding the frequency of anesthetized scanning sessions per animal across longitudinal study designs.
Dental & Oral Research
Dogs remain a standard large-animal model for dental implants, periodontal disease, and bone-regeneration studies.
Beagles are the most commonly used breed in dental research because their jaw size, bone-remodeling rate, and periodontal anatomy are considered translatable to humans. Studies typically involve surgical creation of bone defects, extraction of healthy teeth to create implant sites, induction of peri-implantitis through ligature placement, and months-long observation periods with repeated anesthesia for radiographic assessment.
Dental-implant and bone-graft manufacturers rely on canine data for FDA 510(k) and PMA submissions. Periodontal regeneration studies (guided tissue regeneration, growth-factor scaffolds, stem-cell therapies) use surgically created Class II furcation defects in beagle mandibles as a regulatory-grade efficacy model.
Regulatory driver: FDA guidance for dental devices and biomaterials specifically references canine models as appropriate for demonstrating osseointegration and bone-regeneration endpoints. ISO 7405 (biological evaluation of medical devices used in dentistry) historically assumes large-animal testing for implantable products.
Xenotransplantation
Pig-to-human organ transplantation programs use dogs as intermediate surgical models for technique refinement and immunosuppression testing.
As xenotransplantation moves from experimental to clinical reality (the first pig-heart transplants in humans occurred in 2022–2023), dogs serve as surgical-technique models for organ perfusion, vascular anastomosis, and post-transplant monitoring protocols. Their cardiovascular anatomy and size make them particularly relevant for heart and kidney xenograft studies.
Dogs are also used to test immunosuppression regimens intended to prevent hyperacute and chronic rejection of xenografts, including novel biologics targeting complement activation and T-cell co-stimulation pathways. These studies typically involve major survival surgery with extended post-operative monitoring.
Regulatory driver: FDA xenotransplantation guidance requires preclinical data in appropriate large-animal models demonstrating graft survival, immune-suppression efficacy, and absence of zoonotic pathogen transmission before clinical IND authorization.
Why These Areas Grow While Traditional Tox Declines
NAMs compress toxicology but do not reach emerging domains
New Approach Methodologies (organ-on-chip, in silico ADMET, iPSC cardiomyocyte assays) are validated primarily for safety-pharmacology and repeat-dose toxicology endpoints. They have no equivalent for gene-therapy biodistribution, surgical xenograft models, or whole-animal blast-injury physiology. FDA Modernization Act 2.0 changed statutory language to permit “nonclinical tests” (including in vitro and in silico) without banning animal tests, creating a slow-moving substitution curve that affects traditional tox first.
Minipig substitution is domain-specific
Minipigs increasingly replace dogs in general toxicology and dermal studies, but they are not substitutes in gene therapy (wrong disease models), comparative oncology (no spontaneous tumor registries), or cardiovascular imaging (different cardiac electrophysiology).
Pipeline growth in biologics and advanced therapies
The gene-therapy, cell-therapy, and immuno-oncology pipelines are expanding faster than traditional small-molecule pipelines. Each new modality brings its own nonclinical requirements, many of which specifically demand large-animal models. As long as ICH S12 and FDA biodistribution guidance remain in force, dogs will be structurally embedded in these programs.
Defense spending operates outside pharma economics
Military and homeland-security dog research is driven by mission capability requirements, not drug-approval economics. Budget cycles, threat assessments, and operational needs determine research volume — independent of whether pharmaceutical testing is declining.
Regulatory Anchors by Domain
| Domain | Key Guidance | Effect on Dog Use |
|---|---|---|
| Gene therapy | ICH S12; FDA biodistribution guidance | Mandates large-animal biodistribution studies |
| Immuno-oncology | FDA comparative oncology framework | Positions canine spontaneous tumors as predictive models |
| General tox | ICH M3(R2); FDA Modernization Act 2.0 | Declining; NAMs + minipigs eroding dog requirement |
| Dental/devices | FDA 510(k)/PMA; ISO 7405 | Canine jaw model referenced for implant endpoints |
| Xenotransplantation | FDA xeno guidance; IND requirements | Large-animal surgical models required pre-clinical |
| Biologics (mAbs) | FDA NAMs plan for mAbs | Fastest-declining segment; policy actively phasing out |
| Military/defense | DoD/DHS mission directives | Operationally driven; outside pharma regulatory cycle |